Advertisement

Impact of 18 FDG- PET CT in the Management of Muscle Invasive Bladder Cancer

Published:January 14, 2022DOI:https://doi.org/10.1016/j.clgc.2022.01.009

      Abstract

      Introduction

      Guidelines do not recommend FDG-PET CT for the staging of MIBC as a standard. The objectives of the study are to assess the accuracy of the FDG-PET CT for LN staging and to determine the rate of treatment modification according to FDG-PET CT results in MIBC.

      Patients and methods

      From January 2005 to December 2017, we carried out a retrospective analysis of patients with MIBC who had a FDG-PET CT for staging in two expert centres in Bordeaux, France, and analyzed its clinical value in this setting. Nodal and metastatic staging on CT scan (CT) and FDG-PET CT were done independently.

      Results

      Accuracy of LN staging from CT and FDG-PET CT at initial diagnosis was analyzed in 85 patients (including 70 patients treated with neoadjuvant chemotherapy (NAC)) and compared to pathological examination of resected LN. Sensitivity of FDG-PET CT was better than CT (80.8% versus 26.9%) but the specificity was low (54.2% vs. 83.1%). The Youden index was better for FDG-PET CT (0.35; 0.1 for CT) and FDG-PET CT appeared to be more accurate for determining LN staging of MIBC. FDG-PET CT findings enabled a treatment decision modification in 34/130 patients (26.1%): a therapeutic intensification (9.2%), including surgery not previously planned and/or modified fields of radiotherapy; or a de-escalation (16.9%), mostly avoiding surgery.

      Conclusion

      FDG-PET CT was more sensitive for detection of LN involvement at initial diagnosis of MIBC than CT alone. In our study, treatment decisions were modified, according to FDG-PET CT results, in almost a quarter of patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cowppli-Bony A
        • Uhry Z
        • Remontet L
        • et al.
        Survival of solid cancer patients in France, 1989-2013: a population-based study.
        Eur J Cancer prev. 2017; 26: 461-468
        • Sonpavde G
        • Goldman BH
        • Speights VO
        • et al.
        Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.
        Cancer. 2009; 115: 4104-4109
        • Grossman HB
        • Natale RB
        • Tangen CM
        • et al.
        Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.
        N Engl J Med. 2003; 349: 859-866
        • Rouprêt M
        • Pignot G
        • Masson-Lecomte A
        • et al.
        French ccAFU guidelines — Update 2020- 2022: bladder cancer.
        Prog Urol. 2020; 30: S78-S135
        • Witjes JA
        • Bruins HM
        • Cathomas R
        • et al.
        European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines.
        Eur Urol. 2021; 79: 82-104https://doi.org/10.1016/j.eururo.2020.03.055
        • Horn T
        • Zahel T
        • Adt N
        • et al.
        Evaluation of computed tomography for lymph node staging in bladder cancer prior to radical cystectomy.
        Urol Int. 2016; 96: 51-56
        • Il Oz
        • Altinbas NK
        • Serifoglu I
        • Oz EB
        • Yagci C
        The role of computerized tomography in the assessment of perivesical invasion in bladder cancer.
        Pol J Radiol. 2016; 81: 281-287
        • Woo S
        • Suh CH
        • Kim Y
        • Cho JY
        • Kim SH
        The diagnostic performance of MRI for detection of lymph node metastasis in bladder and prostate cancer: an updated systematic review and diagnostic meta- analysis.
        AJR Am J Roentgenol. 2018; 210: W95-109
        • Apolo AB
        • Riches J
        • Schöder H
        • et al.
        Clinical value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder Cancer.
        J Clin Oncol Sept. 2010; 28: 3973-3978
        • Hitier-Berthault M
        • Ansquer C
        • Branchereau J
        • et al.
        18 Fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study: PET scan for bladder cancer.
        Int J Urol. 2013; 20: 788-796
        • Kibel AS
        • Dehdashti F
        • Katz MD
        • et al.
        Prospective study of [18 F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Staging of Muscle-Invasive Bladder Carcinoma.
        J Clin Oncol. 2009; 27: 4314-4320
        • Girard A
        • Rouanne M
        • Taconet S
        • et al.
        Integrated analysis of 18F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer.
        Eur Radiol. 2019; 29: 4286-4293https://doi.org/10.1007/s00330-018-5959-0
        • Ku Ha H
        • Koo PJ
        • Kim SJ
        Diagnostic accuracy of F-18 FDG PET/CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis.
        Oncology. 2018; 95: 31-38
        • Crozier J
        • Papa N
        • Perera M
        • et al.
        Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis.
        World J Urol. 2019; 37(4) (s00345-018-2439-8): 667-690
        • Mertens LS
        • Fioole-Bruining A
        • Vegt E
        • Vogel WV
        • van Rhijn BW
        • Horenblas S
        Impact of 18 Fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle: FDG-PET/CT in carcinoma invading bladder muscle.
        BJU Int. 2013; 112: 729-734
        • Kollberg P
        • Almquist H
        • Bläckberg M
        • et al.
        [18 F]Fluorodeoxyglucose – positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy.
        Scand J Urol. 2015; 49: 296-301
        • Yang Z
        • Pan L
        • Cheng J
        • et al.
        Clinical value of whole body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of metastatic bladder cancer.
        Int J Urol. 2012; 19: 639-644
        • Goodfellow H
        • Viney Z
        • Hughes P
        • et al.
        Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer: FDG pet in the staging of bladder cancer.
        BJU Int. 2014; 114: 389-395
        • Mertens LS
        • Fioole-Bruining A
        • van Rhijn BWG
        • et al.
        FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer.
        J Urol. 2013; 189: 1687-1691
        • Soubra A
        • Gencturk M
        • Froelich J
        • et al.
        FDG-PET/CT for assessing the response to neoadjuvant chemotherapy in bladder cancer patients.
        Clin Genitourin Cancer. 2018; 16: 360-364
        • Stokkel LE
        • Stokkel MPM
        • Donswijk ML
        • et al.
        The Diagnostic Value of FDG-PET/CT for Urachal Cancer.
        Clin Genitourin Cancer. 2021; 19(5) (S1558-7673(21)00065-3): 373-380
      1. NCCN Clinical Practice Guidelines in Oncology, Bladder Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf (Accessed 6 December, 2021)

        • Paner GP
        • Stadler WM
        • Hansel DE
        • Montironi R
        • Lin DW
        • Amin MB
        Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers.
        Eur Urol. 2018; 73: 560-569
        • Yildirim-Poyraz N
        • Ozdemir E
        • Uzun B
        • Turkolmez S
        Dual phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography with forced diuresis in diagnostic imaging evaluation of bladder cancer.
        Rev Esp Med Nucl E Imagen Mol. 2013; 32: 214-221
        • Voskuilen CS
        • van Gennep EJ
        • Einerhand SMH
        • et al.
        Staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography changes treatment recommendation in invasive bladder cancer.
        Eur Urol Oncol. 2021; 11:S2588-9311(21)00029https://doi.org/10.1016/j. euo.2021.01.005
      2. Abrahamsson J, Kollberg P, Almquist Helen, et al. Compete metabolic response with FDG-PET predicts survival after induction chemotherapy in patients with clinically node positive bladder cancer. doi:10.1111/BJU.15374.